BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8674185)

  • 1. Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
    Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening SA
    Clin Chem; 1996 Jul; 42(7):1026-33. PubMed ID: 8674185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls.
    Oberpenning F; Weining C; Brandt B; De Angelis G; Heinecke A; Hamm M; Stieber P; Hertle L; Schmid HP; Semjonow A
    Eur Urol; 2002 Dec; 42(6):577-82; discussion 582. PubMed ID: 12477653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays.
    Junker R; Brandt B; Zechel C; Assmann G
    Clin Chem; 1997 Sep; 43(9):1588-94. PubMed ID: 9299938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
    Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
    Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
    Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
    Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual monoclonal antibody immunoassay for free prostate-specific antigen.
    Wang TJ; Hill TM; Sokoloff RL; Frankenne F; Rittenhouse HG; Wolfert RL
    Prostate; 1996 Jan; 28(1):10-6. PubMed ID: 8545276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
    Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
    Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer.
    Tello FL; Prats CH; González MD
    Clin Chem Lab Med; 2001 Feb; 39(2):116-20. PubMed ID: 11341744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein.
    Akino H; Suzuki Y; Oyama N; Kanamaru H; Okada K
    Int J Urol; 1999 Sep; 6(9):440-5. PubMed ID: 10510889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.